BetterScholar BetterScholar
8
Role
Title
Level Year L/R
🐜 Stroke Location Is an Independent Predictor of Cognitive Outcome
12 auth. F. Munsch, S. Sagnier, J. Asselineau, A. Bigourdan, C. Guttmann, S. Debruxelles, ... M. Poli, P. Renou, P. Perez, V. Dousset, I. Sibon, T. Tourdias
6 2016
6
🐜
🦁 Early Fiber Number Ratio Is a Surrogate of Corticospinal Tract Integrity and Predicts Motor Recovery After Stroke
11 auth. A. Bigourdan, F. Munsch, P. CoupΓ©, C. Guttmann, S. Sagnier, P. Renou, ... S. Debruxelles, M. Poli, V. Dousset, I. Sibon, T. Tourdias
5 2016
5
🦁
🐜 Thalamic alterations remote to infarct appear as focal iron accumulation and impact clinical outcome
12 auth. GrΓ©gory Kuchcinski, F. Munsch, Renaud Lopes, A. Bigourdan, Jason H Su, S. Sagnier, ... P. Renou, J. Pruvo, B. Rutt, V. Dousset, I. Sibon, T. Tourdias
5 2017
5
🐜
🐜 Major intra-familial phenotypic heterogeneity and incomplete penetrance due to a CACNA1A pathogenic variant.
13 auth. C. AngΓ©lini, J. Van Gils, A. Bigourdan, P. Jouk, D. Lacombe, P. Menegon, S. Moutton, F. Riant, G. SolΓ©, E. Tournier-Lasserve, ... A. Trimouille, M. Vincent, C. Goizet
5 2019
5
🐜
🐜 The Influence of Stroke Location on Cognitive and Mood Impairment. A Voxel-Based Lesion-Symptom Mapping Study.
11 auth. S. Sagnier, F. Munsch, A. Bigourdan, S. Debruxelles, M. Poli, P. Renou, ... S. Olindo, F. Rouanet, V. Dousset, T. Tourdias, I. Sibon
5 2019
5
🐜
🐜 Normal-Appearing White Matter Integrity Is a Predictor of Outcome After Ischemic Stroke
16 auth. S. Sagnier, G. Catheline, B. Dilharreguy, P. Linck, P. CoupΓ©, F. Munsch, A. Bigourdan, S. Debruxelles, M. Poli, S. Olindo, ... P. Renou, F. Rouanet, V. Dousset, S. Berthoz, T. Tourdias, I. Sibon
4 2020
4
🐜
🐜 Chronic Cortical Cerebral Microinfarcts Slow Down Cognitive Recovery After Acute Ischemic Stroke.
13 auth. S. Sagnier, G. Okubo, G. Catheline, F. Munsch, A. Bigourdan, S. Debruxelles, M. Poli, S. Olindo, P. Renou, F. Rouanet, ... V. Dousset, T. Tourdias, I. Sibon
4 2019
4
🐜
🐜 Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment.
8 auth. A. Daste, E. de Mones, L. Digue, L. FranΓ§ois, C. Domblides, C. Dupin, ... A. Bigourdan, A. Ravaud
3 2017
3
🐜